Core A, the Administrative Core of this National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Parkinson's Disease Research Center of Excellence (Udall Center) at the University of Pennsylvania (Penn), will facilitate accomplishing the goals of this multidisciplinary research program. Briefly, the goals of this Udall Center are to elucidate mechanisms of progressive neurodegeneration in Parkinson's disease (PD), especially those mechanisms underlying the cognitive and executive impairments in PD patients without and with dementia (PDD) and in dementia with Lewy bodies (DLB) patients. We hypothesize that disease progression leads to neuron dysfunction and death resulting from the differential transmission of pathologic alpha-synuclein species or strains and their neurotoxic effects in patients with PD/PDD/DLB. Thus, the Aims of Core A are to oversee budgetary and fiscal aspects of this Udall Center;promote and foster interactions between Core and Project investigators, as well as interactions of Udall Center investigators with scientists outside the Center at and beyond Penn;monitor the progress of the Cores and Projects;facilitate the sharing of data, reagents, and resources generated by Penn Udall Center investigators with other researchers in accordance with NIH policies;and participate in annual Udall Center meetings to accelerate the pace of advances in understanding PD/PDD/DLB. By utilizing the strategies in these Aims, Core A will play an important administrative role in this Udall Center by fostering the accomplishment of its overall mission..
Core A is highly relevant to the mission of the Penn Udall Center because it supports the efforts of each of the Cores and Projects in the Center to challenge and re-define current understanding of and research on PD/PDD/DLB by implementing the Specific Aims of Core A.
|Peng, Chao; Gathagan, Ronald J; Covell, Dustin J et al. (2018) Cellular milieu imparts distinct pathological ?-synuclein strains in ?-synucleinopathies. Nature 557:558-563|
|Weintraub, Daniel; Tröster, Alexander I; Marras, Connie et al. (2018) Initial cognitive changes in Parkinson's disease. Mov Disord 33:511-519|
|Wyman-Chick, Kathryn A; Martin, Phillip K; Weintraub, Daniel et al. (2018) Selection of Normative Group Affects Rates of Mild Cognitive Impairment in Parkinson's Disease. Mov Disord 33:839-843|
|Irwin, David J; Hurtig, Howard I (2018) The Contribution of Tau, Amyloid-Beta and Alpha-Synuclein Pathology to Dementia in Lewy Body Disorders. J Alzheimers Dis Parkinsonism 8:|
|Smith, Kara M; Ash, Sharon; Xie, Sharon X et al. (2018) Evaluation of Linguistic Markers of Word-Finding Difficulty and Cognition in Parkinson's Disease. J Speech Lang Hear Res 61:1691-1699|
|Bezdicek, Ondrej; ?ervenková, Markéta; Moore, Tyler M et al. (2018) Determining a Short Form Montreal Cognitive Assessment (s-MoCA) Czech Version: Validity in Mild Cognitive Impairment Parkinson's Disease and Cross-Cultural Comparison. Assessment :1073191118778896|
|Tao, Ye; Peters, Matthew E; Drye, Lea T et al. (2018) Sex Differences in the Neuropsychiatric Symptoms of Patients With Alzheimer's Disease. Am J Alzheimers Dis Other Demen 33:450-457|
|Hoogland, Jeroen; van Wanrooij, Lennard L; Boel, Judith A et al. (2018) Detecting Mild Cognitive Deficits in Parkinson's Disease: Comparison of Neuropsychological Tests. Mov Disord 33:1750-1759|
|Kamps, Sanne; van den Heuvel, Odile A; van der Werf, Ysbrand D et al. (2018) Smaller subcortical volume in Parkinson patients with rapid eye movement sleep behavior disorder. Brain Imaging Behav :|
|Akhtar, Rizwan S; Licata, Joseph P; Luk, Kelvin C et al. (2018) Measurements of auto-antibodies to ?-synuclein in the serum and cerebral spinal fluids of patients with Parkinson's disease. J Neurochem 145:489-503|
Showing the most recent 10 out of 339 publications